Pfizer rejigs top brass, gets chief digital officer on board

By PharmaCompass

2018-10-18

Impressions: 178 Article

A fortnight back, Phispers had reported how Ian Read is to step down as CEO of Pfizer, handing over the baton to the chief operating officer Albert Bourla. Following the change of leadership, Pfizer is also revamping its executive team.

As part of a boardroom shake-up, and owing to the growing importance of digital technology, the American pharmaceutical behemoth has appointed Lidia Fonseca as its chief digital officer in R&D and business process.

Pfizer is following the example of GlaxoSmithKline and Novartis, two big pharma companies that have already appointed chief digital officers to transform R&D and relationships with customers.

Fonseca will be in charge of creating and implementing a “strategy that accelerates and improves the company’s digital capabilities.” At present, she is the chief information officer at Quest Diagnostics and will join Pfizer’s executive leadership team in January.

Other changes at Pfizer include Mikael Dolsten, who will assume oversight of the chief medical officer’s role. Angela Hwang will become group president of Pfizer’s innovative business, responsible for the entire portfolio of innovative medicines. Freda Lewis-Hall will assume a new role as Pfizer’s chief patient officer, advocating on behalf of all patients who rely on Pfizer’s new drugs.

John Young — presently Pfizer’s president of Innovative Health — will assume responsibility for “strategy, business development, portfolio management and valuation activities; business analytics; global commercial operations; and Patient and Health Impact,” among other areas, Pfizer said. Young will also head Pfizer’s consumer healthcare business.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass